KFDA approves first Alzheimer's skin patch
Published: 2007-12-20 06:56:00
Updated: 2007-12-20 06:56:00
The Korea Food and Drug Administration has approved Exelon (rivastigmine) Patch, the first skin patch for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia, according to Novartis Korea.
Exelon (rivastigmine) Patch will be on the market in the latter half of...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
